DOCSLIB.ORG

Piperidine AC-002 34381-68-5 Acebutolol Hydrochlorid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Piperidine AC-002 34381-68-5 Acebutolol Hydrochlorid Email: [email protected] Catalog No. CAS No. Product Name AC-001 154235-83-3 1-(6-Quinoxalinylcarbonyl)-piperidine AC-002 34381-68-5 Acebutolol Hydrochloride AC-003 5438-68-6 O-acetyl mandelic acid AC-004 5080-50-2 Acetyl-L-Carnitine Hydrochloride AC-006 61985-25-9 4-Acetylimidazole AC-007 57756-36-2 4-Acetyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine AC-008 99-96-7 4-Hydroxybenzoic acid AC-009 51037-30-0 Acipimox AC-011 39269-10-8 1,3-Adamantanedicarboxylic acid AC-012 106941-25-7 Adefovir AC-013 50-42-0 Adiphenine Hydrochloride AC-014 56-41-7 L-Alanine AC-015 54965-21-8 Albendazole AC-016 54029-12-8 Albendazole Sulfoxide AC-017 26750-81-2 Alibendol AC-018 80863-62-3 Alitame AC-019 315-30-0 Allopurinol AC-020 481-72-1 Aloeemodin AC-021 850649-62-6 Alogliptin Benzoate AC-022 122852-69-1 Alosetron Hydrochloride AC-023 850-52-2 ALTRENOGEST AC-024 23828-92-4 Ambroxol Hydrochloride AC-025 1750-42-1 3-Amino isoxazole AC-026 149934-21-4 9-Amino minocycline sulphate AC-027 98-16-8 M-amino trifluorotoluene AC-028 455-14-1 4-Aminobenzotrifluoride AC-029 55716-66-0 4-aminobenzocyclobutene AC-030 126325-50-6 3-Amino-2-bromo-4-picoline AC-031 1072-97-5 2-Amino-5-bromopyridine AC-032 84249-14-9 2-Amino-4-bromopyridine AC-033 96-20-8 2-Amino-1-butanol AC-034 13325-10-5 4-Amino-1-butanol AC-035 60-32-2 6-Aminocaproic acid AC-036 121-30-2 4-Amino-6-chloro-benzene-1,3-disulfonic acid diamide Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-037 95-24-9 2-Amino-6-chlorobenzothiazole AC-038 20776-67-4 2-Amino-5-chloro-3-methylbenzoic acid AC-039 3993-78-0 2-Amino-4-Chloropyrimidine AC-040 3814-46-8 2-Aminocycloheptanecarboxylic acid AC-041 75081-40-2 (±)-2-Amino-cyclohexanecarboxylic acid AC-042 27489-62-9 trans-4-Aminocyclohexanol AC-043 156732-15-9 (2S,3S,5S)-5-amino-2-(dibenzylamino)-1,6-diphenyl hexan-3-ol AC-044 120068-79-3 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cycano pyrazole AC-045 43024-15-3 3-Amino-4-ethylpyrazole AC-046 344-80-9 2-Amino-2'-fluoro-5-nitrobenzophenone AC-047 2247-88-3 4-Amino-3-fluoropyridine AC-048 73616-27-0 5-amino-1-(β-hydroxyethyl)pyrazole AC-049 2280-48-0 (R)-2-Amino-3-Hydroxy-3-Methylbutanoic Acid AC-050 6320-39-4 3-Amino-4-hydroxypyridine AC-051 7720-39-0 2-aminoimidazole AC-052 6967-12-0 6-Amino-1H-indazole AC-053 129488-10-4 5-Amino-1H-indazole-1-carboxylic acid, 1,1 dimethyl ethyl ester AC-054 106-60-5 5-Aminolevulinate AC-055 3880-88-4 2-amino-5-methoxytetralin Hydrochloride AC-056 2840-04-2 5-Amino-2-methyl-benzoic acid AC-057 2026-48-4 (S)-(+)-2-Amino-3-methyl-1-butanol AC-058 130912-52-6 (+/-)-3-(Aminomethyl)-5-Methylhexanoic acid AC-059 80082-65-1 (2S-trans)-3-amino-2-methyl-4-oxoazetidine-1-sulfonic acid AC-060 96886-55-4 (S)-2-Amino-2-Methyl-4-Pentenoic Acid AC-061 1904-31-0 3-amino-1-methylpyrazole AC-062 17557-67-4 2-Amino-6-methylsulfonylbenzothiazole AC-063 1588-83-6 4-Amino-3-nitro-benzoic acid AC-064 4570-45-0 2-Amino-oxazole AC-065 137281-39-1 4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl )-ethyl]-benzoic acid Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-066 147027-10-9 (2R,5R)-5-(4-Amino-2-Oxo-2H-Pyrimidin-1-Yl)-[1,3]Oxathiolane -2-Carboxylic Acid,2S-Isopropyl-5-R-Methyl-1R-Cyclohexyl Ester AC-067 5339-85-5 2-amino-phenethylalcohol AC-068 54060-30-9 3-Aminophenylacetylene AC-069 36725-28-7 6-(4-Amino-phenyl)-5-methyl-4,5-dih ydro-2H-pyridazin-3-one AC-070 101328-85-2 (R)-6-(4-Aminophenyl)-5-Methylpyridazin-3(2H)One AC-071 82769-76-4 (S)-3-Amino-3-phenylpropan-1-ol AC-072 13822-56-5 3-Aminopropyltrimethoxysilane AC-073 24242-20-4 5-Amino-2-pyridinecarboxylic acid AC-074 59315-44-5 3-amino-pyridin-2-ol AC-075 86299-47-0 (Z)-2-amino-alpha-[1-(tert-butoxycarbonyl)]-1-1-methylethoxyim ino-4-thiazoleacetic acid AC-076 2150-55-2 2-Amino-4-thiazolinic acid AC-077 73150-67-1 2-(2-Aminothiazol-4-yl) glyoxylic acid AC-078 19774-82-4 Amiodarone hydrochloride AC-079 111470-99-6 Amlodipine besylate AC-080 78613-38-4 Amorolfine Hydrochloride AC-081 1156-92-9 4-Androstenediol AC-082 51025-85-5 Arbekacin AC-083 74-79-3 Arginine AC-084 63358-49-6 Aspoxicillin Trihydrate AC-085 156311-83-0 (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate AC-086 112626-50-3 3-Azabicyclo[3.3.0]octane Hydrochloride AC-088 272-49-1 4-Azaindole AC-089 N/A 4-(2-Azepan-1-yl-ethoxy)-benzaldehyde AC-090 N/A 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(4-benzylox y-phenyl)-3-methyl-1H-indole AC-091 N/A [4-(2-Azepan-1-yl-ethoxy)-phenyl]-methanol AC-092 45347-82-8 Azetidin-3-ol AC-093 117772-70-0 Azithromycin AC-094 2446-83-5 Azodicarboxylic Acid Diisopropyl Ester Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-095 4693-47-4 Azopentanon-C AC-096 27589-33-9 Azosemide AC-097 104757-53-1 Barnidipine Hydrochloride AC-098 2390-63-8 Basic violet 11 AC-099 198481-33-3 Bazedoxifene acetate AC-100 195730-31-5 benzocyclobutene-4-boronic acid AC-101 3469-06-5 benzocyclobutenone AC-102 5350-57-2 Benzophenone hydrozone AC-103 3468-01-7 4H-1-Benzopyran-8-carboxylicacid, 3-methyl-4-oxo-2-phenyl- AC-104 89604-91-1 S-2-Benzothiazolyl(Z) -2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyimino thioacetate AC-105 611-73-4 Benzoyl formoic acid AC-106 7697-46-3 2-benzoylpyrrole AC-107 111865-47-5 Benzyl trimethyl ammonium tribromide AC-108 N/A (S)-3-benzylcarbonyl-5-oxo-4-oxazolidineacetic acid AC-109 93779-31-8 (S)-Benzyl endo, cis-2-azabicyclo [3,3,0]octanecarboxylate Hydrochloride AC-110 51388-20-6 4-Benzyloxyaniline Hydrochloride AC-111 N/A 5-Benzyloxy-2-(4-benzyloxy-phenyl)-1-[4-(2-bromo-ethoxy)-ben zyl]-3-methyl-1H-indole AC-112 N/A 2-{4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylm ethyl]-phenoxy}-ethanol AC-114 198479-63-9 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole AC-115 N/A {4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylmet hyl]-phenoxy}-acetic acid ethyl ester AC-116 35081-45-9 4'-(Benzyloxy)-2-bromopropiophenone AC-117 2086-83-1 Berberine AC-118 633-65-8 Berberine hydrochloride AC-119 1247-42-3 Betapar AC-120 181695-72-7 Valdecoxib AC-121 120410-24-4 biapenem AC-122 N/A Bicyclo[4.2.0]octa-1(6),2,4-triene-2-carboxylic acid AC-123 82657-04-3 Bifenthrin Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-124 58-85-5 Biotin AC-125 138401-24-8 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]biphe nyl-2-carbonitrile AC-126 16150-45-1 Diethyl cromoglycate AC-127 N/A 2-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-isoindole-1,3-dione AC-128 3197-06-6 N,N-BIS(2-HYDROXYETHYL)ETHYLENEDIAMINE AC-129 5538-94-3 Bisoctyl dimethyl ammonium chloride AC-131 91188-13-5 3-Boc-aminoazetidine AC-132 98737-29-2 (2R,3S)-N-Boc-3-amino-1,2-epoxy-4-phenylbutane AC-133 166104-20-7 1-Boc-5-Aminoindole AC-134 135632-53-0 4-(Boc-aminomethyl) piperidine AC-135 66605-57-0 (S)-2-(Boc-amino)-3-phenyl-1-propanol AC-136 625471-18-3 (S)-N-Boc-3-aminopiperidine AC-137 73286-70-1 N-Boc-2,5-dihydropyrrole AC-138 4530-20-5 N-Boc-L-glycine AC-139 109431-87-0 (R)-N-boc-3-hydropyrrolidine AC-141 13726-69-7 Boc-L-Hyp-OH AC-142 147539-41-1 N-Boc-4-methylaminopieridine AC-143 N/A Boc-L-phe(3,4-OH2)-OH AC-144 124443-68-1 N-BOC-Piperidine-4-carboxylic acid methyl ester AC-145 35150-07-3 DL-1-Boc-prolinamide AC-146 122684-34-8 1-Boc-pyrrolidine-3-carboxamide AC-147 140148-70-5 (S)-1-Boc-pyrrolidine-3-carboxylic acid AC-148 147536-97-8 Bosentan AC-149 91714-93-1 Bromfenac Sodium AC-150 5003-71-4 3-Brominepropylamine hydrobromide AC-151 622-88-8 4-Bromophenylhydrazine Hydrochloride AC-152 139042-59-4 2-BROMO-5-ACETYLPYRIDINE AC-153 615-36-1 2-Bromoaniline AC-154 21120-91-2 1-Bromobenzocyclobutene AC-155 73443-85-3 4-Bromo-3H-benzothiazol-2-one AC-156 19472-74-3 2-bromobenzyl cyanide AC-157 1073-39-8 3-Bromo-bicyclo[4.2.0]octa-1,3,5-triene Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No.
Load more

Recommended publications
  • The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: an Observational Study Amgad M
    oepidem ac io m lo r g a y Rabie, Adv Pharmacoepidem Drug Safety 2013, 2:1 h & P Advances in Pharmacoepidemiology & D n i DOI: 10.4172/2167-1052.1000126 r u s g e c ISSN: 2167-1052 S n a a f v e t d y A Drug Safety Research Article Open Access The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: An Observational Study Amgad M. Rabie* Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Dakahlia Governorate, Egypt Abstract In this observational study, we studied the effects of a new drug combination on depression. Patients were analyzed before and after antidepressant treatment using the Hamilton rating scale for depression (HAMD). One group of patients was treated with the new integrated medicine consisting of two separate subcutaneous injections of a low dose (20 mg) of sulpiride and a 2.2 ml complex homeopathic solution based on the Krebs cycle elements; each injection was administered once daily. Another group of patients was treated with conventional therapy of 20 mg sulpiride only. The third group was treated with only the homeopathic solution. The differences in the HAMD scores were evaluated before and after 3 months of treatment in these three groups of patients. The HAMD score showed a statistically significant decrease in the group treated with combined sulpiride and homeopathy. This observation suggests that a low parenteral dose (20 mg) of sulpiride, when administered subcutaneously with a complex homeopathic remedy, may give better therapeutic results for mild and moderate depression than either sulpiride or complex homeopathy alone.
    [Show full text]
  • Update on Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
    J Bras Pneumol. 2015;41(5):454-466 http://dx.doi.org/10.1590/S1806-37132015000000152 REVIEW ARTICLE Update on diagnosis and treatment of idiopathic pulmonary fibrosis José Baddini-Martinez1, Bruno Guedes Baldi2, Cláudia Henrique da Costa3, Sérgio Jezler4, Mariana Silva Lima5, Rogério Rufino3,6 1. Divisão de Pneumologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brasil. 2. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas, ABSTRACT Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil. Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of 3. Disciplina de Pneumologia e Tisiologia, unknown etiology, which is associated with a progressive decrease in pulmonary Faculdade de Ciências Médicas, function and with high mortality rates. Interest in and knowledge of this disorder have Universidade do Estado do Rio de grown substantially in recent years. In this review article, we broadly discuss distinct Janeiro, Rio de Janeiro, Brasil. aspects related to the diagnosis and treatment of idiopathic pulmonary fibrosis. We 4. Ambulatório de Pneumologia, Hospital list the current diagnostic criteria and describe the therapeutic approaches currently Ana Nery, Salvador, Brasil. available, symptomatic treatments, the action of new drugs that are effective in slowing 5. Ambulatório de Doenças Pulmonares Intersticiais, Hospital do Servidor the decline in pulmonary function, and indications for lung transplantation. Público Estadual de São Paulo, São Keywords: Idiopathic pulmonary fibrosis/diagnosis; Idiopathic pulmonary fibrosis/therapy; Paulo, Brasil. Idiopathic pulmonary fibrosis/rehabilitation. 6. Programa de Pós-Graduação em Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • ( 12 ) United States Patent
    US010376507B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 376 , 507 B2 Srinivasan et al. (45 ) Date of Patent: Aug. 13 , 2019 CRESEMBA® ( isavuconazonium sulfate ) , Highlights of Prescrib (54 ) METHOD OF TREATING A PATIENT WITH ing Information , Label ; Patient Information approved by the U . S . A CYP3A4 SUBSTRATE DRUG Food and Drug Administration ; Astellas Pharma US , Inc. ( Licensed from Basilea Pharmaceutics International Ltd . ) , Illinois, USA , Ini (71 ) Applicant: Bow River LLC , Corona Del Mar , CA tial U . S . Approval: 2015 , Revised Mar. 2015 , Reference ID : 3712237, ( US ) 28 pages . DIFLUCAN® ( fluconazole ), Label ; Patient Information , Reference ( 72 ) Inventors : Sundar Srinivasan , Corona Del Mar, ID : 3650838 , Roerig , Division of Pfizer Inc ., New York , NY, Revised Mar. 2013 , 35 pages. CA (US ) ; Christina Chow , Seattle , WA NIZORAL® (ketoconazole )Label ; Patient Information approved by (US ) the U . S . Food and Drug Administration , Reference ID : 3458324 , Copyright 2014 Janssen Pharmaceuticals, Inc . , New Jersey, USA , ( 73 ) Assignee : BOW RIVER LLC , Corona del Mar , Revised Feb . 2014 , 23 pages . NOXAFIL® (posaconazole ) , Highlights of Prescribing Informa CA (US ) tion , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright © 2006 , 2010 , 2013 , 2014 Merck ( * ) Notice : Subject to any disclaimer , the term of this Sharp & Dohme Corp . , a subsidiary of Merck & Co ., Inc ., New patent is extended or adjusted under 35 Jersey , USA , Revised Sep . 2016 , Reference ID : 3983525, 37 pages . U . S . C . 154 (b ) by 0 days. ORAVIG® (miconazole ) , Highlights of Prescribing Information , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright 2012 Praelia Pharmaceuticals , Inc . , North (21 ) Appl.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Addyi Generic Name: Flibanserin Manufacturer
    Brand Name: Addyi Generic Name: Flibanserin Manufacturer: Sprout Pharmaceuticals Drug Class: Central Nervous System Agent, Serotonin Agonist, Dopamine antagonist Uses: Labeled Uses: Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Unlabeled Uses: none. Mechanism of Action: The mechanism of action for flibanserin in the treatment of hypoactive sexual desire disorder is unknown. Flibanserin has high affinity for serotonin (5-hydroxytryptamine or 5-HT) 1A receptors, as an agonist, and 5-HT2A receptors, as an antagonist, and moderate affinity for 5- HT2B, 5-HT2C, and dopamine D4 receptors as an antagonist Pharmacokinetics: Absorption: Tmax 0.75 hours Vd 50L t ½ 11 hours Clearance Not reported Protein binding 98% (albumin) Bioavailability 33% Metabolism: Flibanserin is extensively metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19 to at least 35 metabolites, with most of the metabolites occurring in low concentrations in plasma. Elimination: Flibanserin is primarily excreted through the kidneys in to urine (44%) and feces (51%). Two metabolites could be characterized that showed plasma concentration similar to that achieved with flibanserin: 6,21-dihydroxy-flibanserin-6,21-disulfate and 6- hydroxy-flibanserin-6-sulfate. These two metabolites are inactive. Efficacy: Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med.
    [Show full text]
  • Drug–Drug Salt Forms of Ciprofloxacin with Diflunisal and Indoprofen
    CrystEngComm View Article Online COMMUNICATION View Journal | View Issue Drug–drug salt forms of ciprofloxacin with diflunisal and indoprofen† Cite this: CrystEngComm,2014,16, 7393 Partha Pratim Bag, Soumyajit Ghosh, Hamza Khan, Ramesh Devarapalli * Received 27th March 2014, and C. Malla Reddy Accepted 12th June 2014 DOI: 10.1039/c4ce00631c www.rsc.org/crystengcomm Two salt forms of a fluoroquinolone antibacterial drug, Crystal engineering approach has been effectively ciprofloxacin (CIP), with non-steroidal anti-inflammatory drugs, utilized in recent times in the synthesis of new forms particu- diflunisal (CIP/DIF) and indoprofen (CIP/INDP/H2O), were synthe- larly by exploiting supramolecular synthons. Hence the sized and characterized by PXRD, FTIR, DSC, TGA and HSM. Crystal identification of synthons that can be transferred across Creative Commons Attribution-NonCommercial 3.0 Unported Licence. structure determination allowed us to study the drug–drug different systems is important. For example, synthon trans- interactions and the piperazine-based synthon (protonated ferability in cytosine and lamivudine salts was recently dem- piperazinecarboxylate) in the two forms, which is potentially useful onstrated by Desiraju and co-workers by IR spectroscopy for the crystal engineering of new salt forms of many piperazine- studies.20a Aakeröy and co-workers successfully estab- based drugs. lished the role of synthon transferability (intermolecular amide⋯amide synthons) in the assembly and organization of Multicomponent pharmaceutical forms consisting of an bidentate acetylacetonate (acac) and acetate “paddlewheel” active pharmaceutical ingredient (API) and an inactive 20b complexes of a variety of metal(II)ions. Recently Das et al. co-former,whichisideallyagenerally recognized as safe – have reported the gelation behaviour in various diprimary This article is licensed under a 1 3 (GRAS) substance, have been well explored in recent times.
    [Show full text]
  • DOCTORAL THESIS Effects of Glucocorticoid Overload on Central
    DOCTORAL THESIS Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders Ahmad, Rabia Award date: 2013 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 “Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders” By Rabia Ahmad, BSc (Hons). A thesis submitted in partial fulfilment of the requirements for the degree of PhD Department of Life Sciences University of Roehampton 2013 Abstract Irregularities of the Hypothalamic Pituitary Adrenal (HPA) axis are implicated in stress-related mood disorders. The ensuing long-term elevations in circulating glucocorticoids are associated with neurobiological changes seen in depression. This thesis aims to identify some of the brain mechanisms by which exposure to chronic stress may lead to depression using a preclinical experimental approach.
    [Show full text]
  • Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia
    Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia THE TREATMENT OF THE SCHIZOPHRENIA: AN OVERVIEW Gabriella Galizia School of Pharmacy,University of Salerno, Italy e-mail: [email protected] Summary The schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person. The terms antipsychotic and neuroleptic define a group of medicine principally used to treat schizophrenia, but they are also efficacious for other psychosis and in states of psychic agitation. The antipsychotics are divided into two classes: classic or typical and atypical. The paliperidone, the major metabolite of risperidone, shares with the native drug the characteristics of receptoral bond and of antagonism of serotonin (5HT2A) and dopamine (D2). It's available in a prolonged release formulation and it allows the administration once daily. Besides, the paliperidone has a pharmacological action independent of CYT P450 and in such way a lot of due pharmacological interactions would be avoided to interference with the activity of the CYP2D6, that is known to have involved in the metabolism of the 25% of the drugs of commune therapeutic employment. Introduction The schizophrenia has been a very hard disease to investigate by the research. This is not surprising because it involves the most mysterious aspects of human mind, as emotions and cognitive processes. According to scientific conventions, the schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Table S1. The significant drug pairs in potential DDIs examined by the two databases. Micromedex Drugs.com List of drugs paired PK-PD Mechanism details 1. Amiodarone— PD Additive QT-interval prolongation Dronedarone 2. Amiodarone— PK CYP3A inhibition by Ketoconazole Ketoconazole 3. Ciprofloxacin— PD Additive QT-interval prolongation Dronedarone 4. Cyclosporine— PK CYP3A inhibition by Cyclosporine Dronedarone 5. Dronedarone— PK CYP3A inhibition by Erythromycin Erythromycin 6. Dronedarone— PD Additive QT-interval prolongation Flecainide 7. Dronedarone— PK CYP3A4 inhibition by Itraconazole Itraconazole 8. Dronedarone— PK Contraindication Major CYP3A inhibition by Ketoconazole Ketoconazole 9. Dronedarone— PD Additive QT-interval prolongation Procainamide PD 10. Dronedarone—Sotalol Additive QT-interval prolongation 11. Felodipine— PK CYP3A inhibition by Itraconazole Itraconazole 12. Felodipine— PK CYP3A inhibition by Ketoconazole Ketoconazole 13. Itraconazole— PK CYP3A inhibition by Itraconazole Nisoldipine 14. Ketoconazole— PK CYP3A inhibition by Ketoconazole Nisoldipine 15. Praziquantel— PK CYP induction by Rifampin Rifampin PD 1. Amikacin—Furosemide Additive or synergistic toxicity 2. Aminophylline— Decreased clearance of PK Ciprofloxacin Theophylline by Ciprofloxacin 3. Aminophylline— PK Decreased hepatic metabolism Mexiletine 4. Amiodarone— PD Additive effects on QT interval Ciprofloxacin 5. Amiodarone—Digoxin PK P-glycoprotein inhibition by Amiodarone 6. Amiodarone— PD, PK Major Major Additive effects on QT Erythromycin prolongation, CYP3A inhibition by Erythromycin 7. Amiodarone— PD, PK Flecainide Antiarrhythmic inhibition by Amiodarone, CYP2D inhibition by Amiodarone 8. Amiodarone— PK CYP3A inhibition by Itraconazole Itraconazole 9. Amiodarone— PD Antiarrhythmic inhibition by Procainamide Amiodarone 10. Amiodarone— PK CYP induction by Rifampin Rifampin PD Additive effects on refractory 11. Amiodarone—Sotalol potential 12. Amiodarone— PK CYP3A inhibition by Verapamil Verapamil 13.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]